Literature DB >> 6660926

Double-blind cross-over study with Org OD 14 and placebo in postmenopausal patients.

J Nevinny-Stickel.   

Abstract

double-blind cross-over study with Org OD 14 was done in 35 post-menopausal patients aged 48-69 years who had hot flushes and other associated symptoms. Patients were randomly allocated to Org OD 14 or to placebo as first treatment. Each period of treatment lasted for 6 weeks and there were no intervals between treatments. Tablets containing 2.5 mg of Org OD 14 or placebo tablets of identical appearance were supplied. Patients took one Org OD 14 tablet or one placebo tablet per day. Data on the following variables were obtained and analyzed statistically: hot flushes, sweating, dizziness, palpitation, tiredness, headache, insomnia, irritability, breathlessness, backache, loss of libido, and mood. Assessment was daily in the case of hot flushes and weekly for the other variables. Org OD 14 was statistically significantly more effective in controlling hot flushes, sweating and headache and tended to be better than the placebo tablets for the other variables.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6660926     DOI: 10.1007/bf02114721

Source DB:  PubMed          Journal:  Arch Gynecol        ISSN: 0170-9925


  4 in total

1.  Ovulation-inhibiting properties of Org OD 14.

Authors:  P Franchimont; F Franchi; M Luisi; P M Kicovic
Journal:  Reproduccion       Date:  1982 Apr-Jun

2.  Prospective double-blind trial of synthetic steroid (Org OD 14) for preventing postmenopausal osteoporosis.

Authors:  R Lindsay; D M Hart; A Kraszewski
Journal:  Br Med J       Date:  1980-05-17

3.  Oestrogen therapy and the menopausal syndrome.

Authors:  S Campbell; M Whitehead
Journal:  Clin Obstet Gynaecol       Date:  1977-04

4.  Placebo-controlled cross-over study of effects of Org OD 14 in menopausal women.

Authors:  P M Kicovic; J Cortés-Prieto; M Luisi; S Milojevic; F Franchi
Journal:  Reproduccion       Date:  1982 Apr-Jun
  4 in total
  2 in total

Review 1.  Management of menopause when estrogen cannot be used.

Authors:  R L Young; N S Kumar; J W Goldzieher
Journal:  Drugs       Date:  1990-08       Impact factor: 9.546

Review 2.  Drugs used in the treatment of metabolic bone disease. Clinical pharmacology and therapeutic use.

Authors:  S Patel; A R Lyons; D J Hosking
Journal:  Drugs       Date:  1993-10       Impact factor: 9.546

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.